Targeted treatments after chemoradiotherapy failure in a patient with relapsed, advanced non‑small cell lung cancer with on‑therapy circulating tumor biomarker monitoring: A case report

Bi,Yinghui; Xia,Chaoran; Zhang,Xinglin; Liu,Haixin

doi:10.3892/ol.2023.13993

Targeted treatments after chemoradiotherapy failure in a patient with relapsed, advanced non‑small cell lung cancer with on‑therapy circulating tumor biomarker monitoring: A case report

Authors:
- Yinghui Bi
- Chaoran Xia
- Xinglin Zhang
- Haixin Liu
View Affiliations

Affiliations: Department of Oncology, Qingdao Municipal Hospital, Qingdao, Shandong 266012, P.R. China, Zhejiang Shaoxing Topgen Biomedical Technology Co. Ltd., Shanghai 200120, P.R. China
Published online on: August 2, 2023 https://doi.org/10.3892/ol.2023.13993
Article Number: 407
Copyright: © Bi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ongoing investigations of targeted therapeutic agents and their increased clinical applications, together with research in genomics and proteomics, have explored a variety of novel approaches for treatment of lung cancer, and ‘molecular subtypes’ have been defined based on specific actionable genetic aberrations. Liquid biopsies, including circulating tumor DNA (ctDNA) testing, are of value for cancer diagnosis and comprehensive genomic profiling, such as the identification of cancer subtypes and major genetic alterations in cancer cells. The case of a 66‑year‑old male patient with newly‑diagnosed driver mutation‑negative advanced non‑small cell lung cancer (NSCLC) who underwent conventional therapy is described in the present report. The patient underwent regular monitoring, including continuous ctDNA analysis, imaging and assessment of tumor marker levels such as carcinoembryonic antigen (CEA). The patient initially presented with deep vein thrombosis which affected both lower extremities and without any symptoms in the lung, with a positron emission tomography scan identifying irregular pulmonary nodules in the right lower lobe and enlarged right supraclavicular lymph nodes. Subsequent ultrasound‑guided fine‑needle aspiration with nodule biopsy indicated advanced unresectable disease at stage IIIB based on the Tumor‑Node‑Metastasis staging system by the American Joint Committee on Cancer. Next‑generation sequencing of tumor tissue and peripheral blood confirmed driver mutation‑negative genes, including epidermal growth factor receptor, rat sarcoma, ALK receptor tyrosine kinase, ROS1 proto‑oncogene receptor tyrosine kinase and rearrangement during transfection (RET). After 5 years of chemoradiotherapy and surveillance of ctDNA and CEA levels, detectable kinesin family member 5B (KIF5B)‑RET fusion in ctDNA and rising CEA levels prompted early scans, which identified disease progression. The patient subsequently received the oral RET inhibitor pralsetinib, with treatment being currently ongoing for ≥17 months without detectable KIF5B‑RET ctDNA or elevated CEA levels, with an ongoing minor response and stable disease based on Response Evaluation Criteria in Solid Tumors v1.1 on imaging. The present case illustrates the potential role of on‑therapy circulating tumor biomarker monitoring as a non‑traumatic method to evaluate therapy response and detect early disease progression in patients with advanced NSCLC. Integration of circulating tumor biomarker testing into the management of patients with advanced NSCLC requires additional prospective studies to actively assess and elucidate optimal treatment strategies.

View Figures

View References

1	Houvras YL: Completing the Arc: Targeted inhibition of RET in medullary thyroid cancer. J Clin Oncol. 30:200–202. 2012. View Article : Google Scholar : PubMed/NCBI
2	Santoro M, Melillo RM and Fusco A: RET/PTC activation in papillary thyroid carcinoma: European journal of endocrinology prize lecture. Eur J Endocrinol. 155:645–653. 2006. View Article : Google Scholar : PubMed/NCBI
3	Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL and Kurzrock R: RET aberrations in diverse cancers: Next-Generation sequencing of 4,871 patients. Clin Cancer Res. 23:1988–1997. 2017. View Article : Google Scholar : PubMed/NCBI
4	Li W, Guo L, Liu Y, Dong L, Yang L, Chen L, Liu K, Shao Y and Ying J: Potential unreliability of uncommon ALK, ROS1, and RET genomic breakpoints in predicting the efficacy of targeted therapy in NSCLC. J Thorac Oncol. 16:404–418. 2021. View Article : Google Scholar : PubMed/NCBI
5	Zhang K, Chen H, Wang Y, Yang L, Zhou C, Yin W, Wang G, Mao X, Xiang J, Li B, et al: Clinical characteristics and molecular patterns of RET-Rearranged lung cancer in Chinese patients. Oncol Res. 27:575–582. 2019. View Article : Google Scholar : PubMed/NCBI
6	Gandhi M, Dillon LW, Pramanik S, Nikiforov YE and Wang YH: DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells. Oncogene. 29:2272–2280. 2010. View Article : Google Scholar : PubMed/NCBI
7	Li AY, McCusker MG, Russo A, Scilla KA, Gittens A, Arensmeyer K, Mehra R, Adamo V and Rolfo C: RET fusions in solid tumors. Cancer Treat Rev. 81:1019112019. View Article : Google Scholar : PubMed/NCBI
8	Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, et al: RET, ROS1 and ALK fusions in lung cancer. Nat Med. 18:378–381. 2012. View Article : Google Scholar : PubMed/NCBI
9	Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, et al: KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 18:375–377. 2012. View Article : Google Scholar : PubMed/NCBI
10	Chen P, Liu Y, Wen Y and Zhou C: Non-small cell lung cancer in China. Cancer Commun (Lond). 42:937–970. 2022. View Article : Google Scholar : PubMed/NCBI
11	Qiu Z, Ye B, Wang K, Zhou P, Zhao S, Li W and Tian P: Unique genetic characteristics and clinical prognosis of female patients with lung cancer harboring RET fusion gene. Sci Rep. 10:103872020. View Article : Google Scholar : PubMed/NCBI
12	Pikor LA, Ramnarine VR, Lam S and Lam WL: Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 82:179–189. 2013. View Article : Google Scholar : PubMed/NCBI
13	Shim HS, Choi YL, Kim L, Chang S, Kim WS, Roh MS, Kim TJ, Ha SY, Chung JH, Jang SJ, et al: Molecular testing of lung cancers. J Pathol Transl Med. 51:242–254. 2017. View Article : Google Scholar : PubMed/NCBI
14	Chan BA and Hughes BG: Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. Transl Lung Cancer Res. 4:36–54. 2015.PubMed/NCBI
15	Lim C, Tsao MS, Le LW, Shepherd FA, Feld R, Burkes RL, Liu G, Kamel-Reid S, Hwang D, Tanguay J, et al: Biomarker testing and time to treatment decision in patients with advanced non small-cell lung cancer. Ann Oncol. 26:1415–1421. 2015. View Article : Google Scholar : PubMed/NCBI
16	Janse van Rensburg HJ, Spiliopoulou P and Siu LL: Circulating biomarkers for therapeutic monitoring of anti-cancer agents. Oncologist. 27:352–362. 2022. View Article : Google Scholar : PubMed/NCBI
17	Duffy MJ and Crown J: Circulating Tumor DNA as a biomarker for monitoring patients with solid cancers: Comparison with standard protein biomarkers. Clin Chem. 68:1381–1390. 2022. View Article : Google Scholar : PubMed/NCBI
18	Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, Shirasu H, Yamazaki K, Watanabe J, Kotaka M, et al: Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 29:127–134. 2023. View Article : Google Scholar : PubMed/NCBI
19	Zhao H, Chen KZ, Hui BG, Zhang K, Yang F and Wang J: Role of circulating tumor DNA in the management of early-stage lung cancer. Thorac Cancer. 9:509–515. 2018. View Article : Google Scholar : PubMed/NCBI
20	Lim W, Ridge CA, Nicholson AG and Mirsadraee S: The 8th lung cancer TNM classification and clinical staging system: Review of the changes and clinical implications. Quant Imaging Med Surg. 8:709–718. 2018. View Article : Google Scholar : PubMed/NCBI
21	Kaba H, Fukuda H, Yamamoto S and Ohashi Y: Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0. Gan To Kagaku Ryoho. 31:1187–1192. 2004.(In Japanese). PubMed/NCBI
22	Brodovicz KG, McNaughton K, Uemura N, Meininger G, Girman CJ and Yale SH: Reliability and feasibility of methods to quantitatively assess peripheral edema. Clin Med Res. 7:21–31. 2009. View Article : Google Scholar : PubMed/NCBI
23	Azam F, Latif MF, Farooq A, Tirmazy SH, AlShahrani S, Bashir S and Bukhari N: Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol. 12:728–736. 2019. View Article : Google Scholar : PubMed/NCBI
24	Kelly CM and Shahrokni A: Moving beyond Karnofsky and ECOG performance status assessments with new technologies. J Oncol. 2016:61865432016. View Article : Google Scholar : PubMed/NCBI
25	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
26	Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, et al: Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 7:1394–1403. 2017. View Article : Google Scholar : PubMed/NCBI
27	Arrieta O, Villarreal-Garza C, Martínez-Barrera L, Morales M, Dorantes-Gallareta Y, Peña-Curiel O, Contreras-Reyes S, Macedo-Pérez EO and Alatorre-Alexander J: Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: A prospective cohort study. BMC Cancer. 13:2542013. View Article : Google Scholar : PubMed/NCBI
28	Kuo YS, Zheng MY, Huang MF, Miao CC, Yang LH, Huang TW and Chou YT: Association of divergent carcinoembryonic antigen patterns and lung cancer progression. Sci Rep. 10:20662020. View Article : Google Scholar : PubMed/NCBI
29	Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
30	Shen T, Pu X, Wang L, Yu Z, Li J, Zhang Y, Liang X, Chen H, Xu C, Song Z and Wang W: Association between RET fusions and efficacy of pemetrexed-based chemotherapy for patients with advanced NSCLC in China: A multicenter retrospective study. Clin Lung Cancer. 21:e349–e354. 2020. View Article : Google Scholar : PubMed/NCBI
31	Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, et al: Targeting RET in patients with RET-Rearranged lung cancers: Results from the global, multicenter RET registry. J Clin Oncol. 35:1403–1410. 2017. View Article : Google Scholar : PubMed/NCBI
32	Drilon A, Bergagnini I, Delasos L, Sabari J, Woo KM, Plodkowski A, Wang L, Hellmann MD, Joubert P, Sima CS, et al: Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Ann Oncol. 27:1286–1291. 2016. View Article : Google Scholar : PubMed/NCBI
33	König D, Savic Prince S and Rothschild SI: Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations. Cancers (Basel). 13:8042021. View Article : Google Scholar : PubMed/NCBI
34	Zhou Q, Wu Y, Chang J, Wang H, Fan Y, Wang K, Wu G, Nian W, Sun Y, Sun M, et al: Efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion+ non-small cell lung cancer after platinum-based chemotherapy. J Thorac Oncol. 16:216–227. S1002021. View Article : Google Scholar
35	Subbiah V, Cassier PA, Siena S, Garralda E, Paz-Ares L, Garrido P, Nadal E, Vuky J, Lopes G, Kalemkerian GP, et al: Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat Med. 28:1640–1645. 2022. View Article : Google Scholar : PubMed/NCBI
36	Supplee JG, Milan MSD, Lim LP, Potts KT, Sholl LM, Oxnard GR and Paweletz CP: Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA. Lung Cancer. 134:96–99. 2019. View Article : Google Scholar : PubMed/NCBI
37	Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, et al: Liquid biopsy for advanced non-small cell lung cancer (NSCLC): A statement paper from the IASLC. J Thorac Oncol. 13:1248–1268. 2018. View Article : Google Scholar : PubMed/NCBI
38	Tsuta K, Kohno T, Yoshida A, Shimada Y, Asamura H, Furuta K and Kushima R: RET-rearranged non-small-cell lung carcinoma: A clinicopathological and molecular analysis. Br J Cancer. 110:1571–1578. 2014. View Article : Google Scholar : PubMed/NCBI
39	Lin C, Wang S, Xie W, Chang J and Gan Y: The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: A meta-analysis. Cancer Biol Ther. 16:1019–1028. 2015. View Article : Google Scholar : PubMed/NCBI
40	Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM, et al: Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res. 24:1872–1880. 2018. View Article : Google Scholar : PubMed/NCBI
41	Sanz-Garcia E, Zhao E, Bratman SV and Siu LL: Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges. Sci Adv. 8:eabi86182022. View Article : Google Scholar : PubMed/NCBI
42	Caswell DR and Swanton C: The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med. 15:1332017. View Article : Google Scholar : PubMed/NCBI
43	Shi X, Huang F, Chen A, Wu Z, Huang Q, Liang Y, Zhou Q, Mo H, Li X and Zhang J: The impact of chemotherapy on EGFR mutation status in non-small-cell lung cancer: A meta-analysis. Open J Gen. 7:117–129. 2017. View Article : Google Scholar
44	Pich O, Muiños F, Lolkema MP, Steeghs N, Gonzalez-Perez A and Lopez-Bigas N: The mutational footprints of cancer therapies. Nat Genet. 51:1732–1740. 2019. View Article : Google Scholar : PubMed/NCBI
45	Strom SP: Current practices and guidelines for clinical next-generation sequencing oncology testing. Cancer Biol Med. 13:3–11. 2016. View Article : Google Scholar : PubMed/NCBI
46	Hsiehchen D, Espinoza M, Gerber DE and Beg MS: Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay. Cancer Biol Ther. 22:455–464. 2021. View Article : Google Scholar : PubMed/NCBI
47	Parikh AR, Mojtahed A, Schneider JL, Kanter K, Van Seventer EE, Fetter IJ, Thabet A, Fish MG, Teshome B, Fosbenner K, et al: Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers. Clin Cancer Res. 26:1877–1885. 2020. View Article : Google Scholar : PubMed/NCBI